Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Launched by CANADIAN CANCER TRIALS GROUP ·

Keywords

ClinConnect Summary

This clinical trial is studying whether a new treatment using two immunotherapy drugs, botensilimab and balstilimab, can help people with colorectal cancer that cannot be removed by surgery and has not responded to chemotherapy. The main goal is to find out if these drugs can help patients live longer. The study will also look at whether the treatment can improve quality of life, slow down or shrink tumors, and identify any signs in the tumor or blood that might predict who benefits the most. Researchers will also carefully check the safety of these drugs and how the body processes them.

The trial is open to adults aged 65 to 74 with colorectal cancer that cannot be removed by surgery and who have already tried chemotherapy without success. People of all genders may participate. If you join, you might receive the new immunotherapy treatment or the best supportive care, which focuses on managing symptoms and improving comfort. The study is not yet recruiting participants, but it aims to offer a new option for those with limited treatments available.

Gender

ALL

Eligibility criteria